摘要
EB病毒(Epstein-Barr virus,EBV)属于人类疱疹病毒γ亚科,是首个被鉴定的人类致瘤病毒.EBV感染与人传染性单核细胞增多症、多种淋巴瘤及上皮细胞肿瘤的发生发展密切相关,每年全球因EBV相关肿瘤新增病例超过20万,死亡病例超14万,造成巨大的公共卫生和经济负担.然而,目前尚无有效药物和疫苗获批上市.靶向病毒的特异性抗体是病毒学研究的重要工具.EBV中和抗体主要针对病毒包膜表面的糖蛋白,这些糖蛋白在感染过程中发挥关键作用.对中和抗体的特性和功能研究,不仅有助于深入理解病毒感染机制,还为疫苗的理性设计提供了指导.此外,因其优异的体内外中和活性,这些抗体有望应用于EBV感染及相关疾病的治疗和预防.本文系统综述了靶向EBV不同包膜糖蛋白的中和抗体,归纳其功能活性、结合表位及中和机制,为EBV治疗性药物和疫苗的研发提供理论依据.
Epstein-Barr virus(EBV),a member of the human herpesvirusγsubfamily,is the first identified human oncogenic virus.EBV infection is closely associated with the development of infectious mononucleosis,various lymphomas,and epithelial cell tumors,contributing to over 200000 tumor cases and more than 140000 deaths globally each year.This significant public health and economic burden underscores the urgent need for effective therapeutics and vaccines.Currently,no approved drugs or vaccines specifically target EBV.Neutralizing antibodies,which primarily target glycoproteins on the EBV envelope involved in viral entry,serve as valuable tools for virological research.Evaluating the properties and functional activities of these antibodies enhances our understanding of EBV infection mechanisms and informs rational vaccine design.Additionally,neutralizing antibodies exhibit potent in vivo and in vitro activity,offering promising potential for the prevention and treatment of EBV infections and associated diseases.This review systematically explores neutralizing antibodies targeting EBV envelope glycoproteins,summarizing their functional characteristics,binding epitopes,and neutralizing mechanisms.By providing insights into these antibodies,the article aims to establish a robust theoretical foundation for the development of therapeutic drugs and vaccines against EBV.
作者
洪俊平
钟玲
张琬琳
郑清炳
徐淼
陈毅歆
夏宁邵
张晓
HONG JunPing;ZHONG Ling;ZHANG WanLin;ZHENG QingBing;XU Miao;CHEN YiXin;XIA NingShao;ZHANG Xiao(College of Pharmacy,Chongqing Medical University,Chongqing 400016,China;State Key Laboratory of Vaccines for Infectious Diseases,National Institute of Diagnostics and Vaccine Development in Infectious Diseases,Xiamen University,Xiamen 361005,China;State Key Laboratory of Oncology in South China,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou 510060,China;The University of Texas Health Science Center at Houston,Houston 77030,USA)
出处
《中国科学：生命科学》
CSCD
北大核心
2024年第12期2385-2398,共14页
Scientia Sinica(Vitae)
基金
国家自然科学基金(批准号:82371832)
重庆市自然科学基金(批准号:2023NSCQ-MSX1536)
重庆市教育委员会科学技术研究计划(批准号:KJZD-M202400401,KJQN-202300453)资助。
关键词
EB病毒
糖蛋白
中和抗体
优势表位
中和机制
Epstein-Barr virus
glycoprotein
neutralizing antibody
immunodominant epitope
neutralizing mechanism
